Does the therapy with uric acid lowering (ULT) agents reduce the rate of progression of CKD? Does it reduce the risk of cardiovascular events? The following article explored the questions.
Article name: Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis
This article was published in PLOS One in 2017. It is a meta-analysis of 16 randomized controlled trials. ULT produced:
- A 55% relative risk (RR) reduction (95% confidence interval [95% CI], 31-64) for kidney failure events (p<0.001)
- A 60% RR reduction (95% CI, 17-62) for cardiovascular events (p<0.001)
- No significant effect on the mortality risk (RR, 0.86; 95% CI, 0.50-1.46).